Hemodialysis

Global Dialysis Market (2022 to 2027) - Featuring Baxter International, Fresenius Medical Care and DaVita Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, February 7, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, Hypertension, Peritoneum, Prevalence, Stomach, Arteriovenous fistula, Industry, Growth, Chronic kidney disease, Renal replacement therapy, Product-service system, Creatinine, Coronavirus, Kidney, Incidence, Waste, ESRD, Patient, Equipment, Peritoneal dialysis, Urea, Blood, Kidney disease, Dialysis, CKD, Renal failure index, Kidney transplantation, Lists of countries and territories, Diabetes, Pharmaceutical industry, Hemodialysis

Over the last decade, the rising prevalence of chronic kidney diseases has increased, leading to market growth.

Key Points: 
  • Over the last decade, the rising prevalence of chronic kidney diseases has increased, leading to market growth.
  • Remarkably, dialysis is a preferred technique over kidney transplantation, which is expected to boost the dialysis market further.
  • Besides, improved reimbursement policies for renal therapy by private and public institutions at a remarkable rate also encourage the expansion of the market.
  • By type, the global dialysis market is characterized by haemodialysis and peritoneal dialysis.

Non-profit Northwest Kidney Centers Celebrates 60th Anniversary

Retrieved on: 
Monday, January 10, 2022
People, Health, Puget Sound, Education, Kidney disease, Risk, Dialysis, Chronic kidney disease, Death, Patient, Hospital, Hope, Center, Northwest Kidney Centers, Research, Kidney, Black, Hemodialysis, University, Community, Life, Kidney failure, Fox, University of Washington, Pharmaceutical industry, Health insurance

SEATTLE, Jan. 10, 2022 /PRNewswire/ -- Northwest Kidney Centers , the world's first dialysis organization, is launching a year-long celebration to honor its 60th anniversary.

Key Points: 
  • SEATTLE, Jan. 10, 2022 /PRNewswire/ -- Northwest Kidney Centers , the world's first dialysis organization, is launching a year-long celebration to honor its 60th anniversary.
  • "People with kidney disease are not always aware of their many options," said Dr. Suzanne Watnick, Northwest Kidney Centers Chief Medical Officer.
  • As a community-based nonprofit, Northwest Kidney Centers' mission is to treat patients throughout their kidney disease journey.
  • Northwest Kidney Centers is a regional, not-for-profit, community-based provider of kidney dialysis, public health education and research into the causes and treatments of chronic kidney disease.

Quanta Announces Formation of North American Medical Advisory Board

Retrieved on: 
Wednesday, September 1, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, San Diego Magazine, Toronto General Hospital, Peritoneal dialysis, Leadership, Biomarker, Natera, Royal college, Research, CMO, Health, Clinical Journal of the American Society of Nephrology, United Kingdom, Hypertension, Internal medicine, Medicine, University, Population health, National Kidney Foundation, ICU, Royal College of Physicians and Surgeons of Canada, Associate, CEO, Kidney disease, Genetic testing, Hospital, Freedom, American Society of Nephrology, University Health Network, Dialysis, Waste, SC, Cincinnati, United, University Hospitals Ahuja Medical Center, Chronic kidney disease, University of Pittsburgh Medical Center, MAB, Food and Drug Administration, FDA, Prescription, Physician, Society, Economics, Kidney, Kidney failure, Patient, Renal replacement therapy, FRCPC, Medical device, Pharmaceutical industry, Hemodialysis, Quanta and SC+, HEMODIALYSIS, QUANTA AND SC+

Quanta Dialysis Technologies Ltd (Quanta or the Company), a medical technology leader delivering on its vision to give control to dialysis users through more flexible and accessible dialysis care, announced today the formation of a North American Medical Advisory Board (MAB).

Key Points: 
  • Quanta Dialysis Technologies Ltd (Quanta or the Company), a medical technology leader delivering on its vision to give control to dialysis users through more flexible and accessible dialysis care, announced today the formation of a North American Medical Advisory Board (MAB).
  • The Medical Advisory Board consists of prominent nephrologists and is chaired by Dr. Paul Komenda, chief medical officer (CMO) at Quanta.
  • I am thrilled to welcome this diverse group of nephrologists who are performing at the top of their field to our North American Medical Advisory Board, said Dr. Komenda.
  • Members of Quantas North American Medical Advisory Board include:
    Dr. Christos Argyropoulos, MD: Dr. Christos Argyropoulos is the division chief of nephrology at the University of New Mexico Health Sciences Center.

Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021

Retrieved on: 
Thursday, July 29, 2021
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Rockwell Medical, Hemodialysis, Dialysis, Nephrology, Artificial kidney

ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.

Key Points: 
  • ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.
  • A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/ .
  • The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform.
  • In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.

Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Retrieved on: 
Thursday, July 29, 2021
Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Medicine, Clinical medicine, Medical specialties, Membrane technology, Renal dialysis, Kidney diseases, Primary hyperoxaluria, Hyperoxaluria, Alnylam Pharmaceuticals, Hemodialysis, Lumasiran, Oxalate, Lumasiran, Primary Hyperoxaluria Type 1 (PH1), RNAi, Alnylam Pharmaceuticals, LUMASIRAN, PRIMARY HYPEROXALURIA TYPE 1 (PH1), RNAI, ALNYLAM PHARMACEUTICALS

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function.
  • Results of the primary analysis at six months demonstrated substantial reduction in plasma oxalate from baseline in patients (N=21) with advanced disease, including those on hemodialysis.
  • Cohort A enrolled six patients with advanced PH1 who do not yet require dialysis, and Cohort B enrolled 15 patients who are hemodialysis-dependent.
  • Lumasiran also demonstrated positive results across key secondary endpoints, including measures of urinary oxalate (for patients in Cohort A) and additional measures of plasma oxalate.

New Studies Demonstrate Role of High-Flux Dialyzers in Managing Albumin

Retrieved on: 
Thursday, July 29, 2021
Blood proteins, Branches of biology, Medicine, Hypoalbuminemia, Anatomy, Serum albumin, Serum, Albumin, Hemodialysis

This real-world analysis evaluated the performance of four high-flux dialyzers with varying surface areas in 271 patients with baseline hypoalbuminemia.

Key Points: 
  • This real-world analysis evaluated the performance of four high-flux dialyzers with varying surface areas in 271 patients with baseline hypoalbuminemia.
  • "This study further demonstrates that high-flux dialyzers can play a role in increasing albumin levels, and especially for those patients with higher body mass index and inflammation."
  • "These results further reinforce the important role that high-flux dialyzers like Optiflux can play in helping address the potential dangers of low serum albumin levels."
  • The authors note that "excessive" loss of albumin is a theoretical concern with the chronic use of increasingly permeable dialyzers.

Quanta to Present at the LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Monday, July 19, 2021
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Hemodialysis, Dialysis, Home hemodialysis

Headquartered in the UK and with operations inthe US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.

Key Points: 
  • Headquartered in the UK and with operations inthe US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.
  • Quantas lead product, SC+, is a small and simple, powerful hemodialysis system designed to providegreater freedom and flexibility in the delivery of life sustaining dialysis treatments.
  • The simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control oftheir lives with selfcare and home dialysis.
  • Meanwhile, as a compact, portable and versatile device, SC+provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.

Diality Poised to Revolutionize Dialysis Treatment - In Development of Versatile Home Dialysis System; Welcomes Industry Veteran Dan Guthrie as Chief Business Officer

Retrieved on: 
Tuesday, July 6, 2021
Medicine, Membrane technology, Given names, Renal dialysis, Articles, Detoxification, Dialysis, Hemodialysis, Leadership, Osman

Founded in 2014, Diality is currently developing a versatile hemodialysis system that addresses a variety of unmet needs for a rapidly evolving dialysis industry.

Key Points: 
  • Founded in 2014, Diality is currently developing a versatile hemodialysis system that addresses a variety of unmet needs for a rapidly evolving dialysis industry.
  • "After an extensive search, Diality is excited to welcome Dan Guthrie to our executive leadership team," said Osman Khawar, M.D., CEO of Diality.
  • Further, his experience in market development and capital equipment and recurring revenue business models are an excellent fit for our company."
  • Dan Guthrie brings over20 years of senior leadership and commercialization experience to Diality.

Satellite Healthcare Participates in Clinical Trial With Home Hemodialysis Machine

Retrieved on: 
Monday, June 14, 2021
Health, Clinical trials, Medical devices, Medicine, Clinical medicine, Renal dialysis, Membrane technology, Nephrology, Home hemodialysis, Hemodialysis, Dialysis, Deka

Satellite Healthcare today announced it will participate in an ongoing clinical trial sponsored by DEKA Research & Development Corp. (DEKA).

Key Points: 
  • Satellite Healthcare today announced it will participate in an ongoing clinical trial sponsored by DEKA Research & Development Corp. (DEKA).
  • The study is investigating the clinical use of the HemoCare Hemodialysis System, a new home hemodialysis machine that has been designed by DEKA with a goal to make overnight hemodialysis safer and easier to perform.
  • We are proud to bring this opportunity to our dialysis patients in the Austin market, said Dr. Brigitte Schiller, Chief Medical Officer at Satellite Healthcare.
  • The trial, conducted with study partner CVS Kidney Care, will assess the safety and performance of the HemoCare Hemodialysis System.

Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

Retrieved on: 
Friday, June 11, 2021
Medicine, Clinical medicine, Bad Homburg vor der Höhe, Membrane technology, Health care, Renal dialysis, Private providers of NHS services, Fresenius, Societates Europaeae, Laura Niklason, Hemodialysis, Dialysis

Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and economic perspectives.

Key Points: 
  • Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and economic perspectives.
  • Under a Distribution Agreement entered into in June 2018, Fresenius Medical Care obtained the exclusive global rights to commercialize Humacytes HAVs in the applications of vascular access for hemodialysis and peripheral arterial disease.
  • We are pleased to expand our partnership with Fresenius Medical Care, the worlds leading care provider for patients undergoing kidney replacement therapy, said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte.
  • Fresenius Medical Care has a network of more than 4,000 dialysis centers worldwide, and cares for over 300,000 patients with end-stage renal failure.